Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response

Loo, C.Alonzo, A.Barton, D.Berk, M.Chatterton, M.L.Dong, V.Gálvez, V.Mills, N.T.Mitchell, P.B.Sarma, S.Somogyi, A.A.Rodgers, A.2025-09-222025-09-222025The British journal of psychiatry. Supplement, 2025; 226(5):317-3180007-12501472-1465https://hdl.handle.net/2440/147489CommentaryAbstract is not availableen© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists.Ketamine/esketamine; major depressive disorder; clinical drug studies; neuroscience; affective disorders; commentaryEfficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author responseJournal article10.1192/bjp.2024.176742428Mills, N.T. [0000-0003-3255-5118]Somogyi, A.A. [0000-0003-4779-0380]